Josefina Puig is the CSO and co-founder of Kinzbio, with a background in biology from the University of the Republic in Uruguay, where she specialized in the genetic characterization of veterinary viruses. During the COVID-19 pandemic, while contributing to Uruguay’s national response at Institut Pasteur Montevideo, she was confronted with the clinical impact of hospital-acquired infections and antimicrobial resistance (AMR), a turning point that led her to co-found Kinzbio in 2021. After serving as both CEO and CSO during the company’s early stages, securing initial funding and establishing its proprietary phage therapy platform, she transitioned in 2023 to focus exclusively on the CSO role, leading a multidisciplinary team and driving the scientific, technological, and clinical development of phage-based therapies aimed at addressing AMR in Latin America.